Celecoxib clinical profile

Rheumatology

Volumn 39, Issue SUPPL. 2, 2000, Pages 21-28

  Tive, L ^a  

^a PFIZER INC   (United States)

Author keywords

Celecoxib; COX 2 inhibitors; Gastrointestinal safety; NSAIDs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUCONAZOLE; GLIBENCLAMIDE; IBUPROFEN; KETOCONAZOLE; LITHIUM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; TOLBUTAMIDE; WARFARIN;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELDERLY CARE; ENZYME INHIBITION; FLATULENCE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; VOMITING;

EID: 0034470372     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.suppl_2.21     Document Type: Article

References (53)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity
3. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice
4. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
5. TIS10, A phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
6. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
7. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme
8. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
9. COX-1 and COX-2 tissue expression: Implications and predictions
10. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide
11. The role of cyclooxygenase in inflammation, cancer, and development
12. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
13. Cyclooxygenase in biology and disease
14. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
15. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
16. 14C]celecoxib in healthy male volunteers
17. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
18. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
19. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects
20. Clinical pharmacokinetics of naproxen
21. Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam
22. Effects of diclofenac on lithium kinetics
23. Celecoxib biotransformation: Fluconazole but not ketoconazole substantially increases celecoxib exposure in man
24. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
25. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee
26. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib
27. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip
28. Efficacy and tolerability of celecoxib: A comparison of once-daily vs twice-daily dosing
29. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis
30. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
31. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
32. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: An international multicentre collaborative study
33. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
34. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
35. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs
36. Safety and efficacy of celecoxib, a specific COX-2 inhibitor in patients with rheumatoid arthritis
37. Early experience with selective COX-2 inhibitors: Safety profile in over 340,000 patients years of use
38. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
39. Review article: Non-steroidal anti-inflammatory drug-induced gastrointestinal permeability
40. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
41. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
42. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
43. COX2 selective NSAIDs and renal function: Gain without pain?
44. Renal effects of selective cyclooxygenase-2 inhibition in normatensive salt-depleted subjects
45. Effects of celecoxib and naproxen on renal function in the elderly
46. NSAIDs and increased blood pressure. What is the clinical significance?
47. The impact of nonsteroidal anti-inflammatory drugs on hypertension; alternative analgesics for patients at risk
48. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
49. Consumption of NSAIDs and the development of congestive heart failure in elderly patients
50. D716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
51. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
52. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain